Zacks Investment Research
03 Jul 2026, 18:40 UTC · 11w ago
Verdict
Headline takes no side. We score HAE +0.40 across four claims — moderately bullish.
+0.40moderately bullish
More positive than 65% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Haemonetics' Plasma franchise returned to growth in Q4 fiscal 2026 with organic revenue growth of 13%.
More positive than 77% of claims this week
Haemonetics signed new long-term agreements with BioLife and Grifols in fiscal 2025.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 64% of claims this week
Haemonetics faces challenges from a debt-burdened balance sheet and fierce competitive pressure.
So whatHigh debt and competition act as headwinds to valuation and operational margins.
More negative than 78% of claims this week
The company's shares have lost 2.4% over the past year, underperforming the S&P 500's 22.8% growth.
More negative than 65% of claims this week
Which stocks this story touches
More positive than 65% of ticker scores this week
Positive growth in Plasma franchise and NexSys PCS adoption, though tempered by debt and competition.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+42.9%
Price agrees with the score
$107.28 vs $75.07 close before publication (Jul 2) · not market-adjusted
HAE chart →